Core Insights - iRhythm Technologies Inc. anticipates full-year 2025 revenue to exceed $740 million, driven by record revenue unit volume in Q4 2025, surpassing analysts' consensus of $737.95 million [1] - For fiscal year 2026, iRhythm expects revenue between $870 million and $880 million, reflecting a year-over-year growth of approximately 17% to 18%, compared to the consensus of $862.68 million [2] - The company projects an adjusted EBITDA margin of approximately 11.5% to 12.5% for 2026 [2] Growth Catalysts - iRhythm is positioned to accelerate growth through multiple catalysts, including deeper penetration in primary care and population health via AI-powered risk stratification partnerships, momentum in mobile cardiac telemetry, expansion into adjacent markets like obstructive sleep apnea, and continued international execution [3] Market Reaction - Following the update, iRhythm's stock fell around 20%, attributed to the delay of the Zio MCT launch to 2027 and formal 2026 guidance that did not meet market expectations [4] - Analyst Brandon Vazquez believes the stock weakness is overblown and recommends buying shares, adding iRhythm to the William Blair Analyst Conviction List due to favorable growth prospects and valuation reset [5] Management Insights - Management had previously hinted at a delay for Zio MCT, and the recent conference made this explicit, leading to adjustments in buy-side models regarding MCT contributions in 2026 [6] - William Blair does not foresee any FDA issues that iRhythm cannot address in a reasonable timeframe, and the expected 2027 launch allows for flexibility in case of additional agency requests [6] Stock Performance - iRhythm shares were trading at $155.44, up 1.23% at the time of publication, indicating some recovery amidst the recent stock volatility [7]

Core Insights - The company expects revenue for full year 2026 to be approximately $870 million to $880 million, reflecting a year-over-year growth of about 17% to 18% [1] - The anticipated adjusted EBITDA margin for 2026 is projected to be around 11.5% to 12.5% [1] - The year 2025 has been described as transformative for the company, achieving over 25% year-over-year revenue growth and free cash flow positivity for the first time [1] Company Performance - The company has executed strong commercial volumes and aims to drive best-in-class quality systems [1] - The comprehensive clinical evidence program, including AVALON and CAMELOT publications, supports the clinical superiority of Zio LTCM and market expansion [1] - The company is well-positioned for growth with multiple catalysts, including deeper penetration in primary care and population health through AI partnerships [1] Market Expansion - The company plans to expand into adjacent markets such as obstructive sleep apnea and continue its international execution [1] - There is a focus on mobile cardiac telemetry and leveraging AI-powered risk stratification partnerships to enhance market presence [1] - The company expresses confidence in delivering sustainable, profitable growth while transforming cardiac care for millions of patients globally [1]

Core Insights - iRhythm Technologies, Inc. has reported a transformative year in 2025, achieving over 25% year-over-year revenue growth and free cash flow positivity for the first time in its history [3] Operational Highlights - The company has recorded strong commercial volumes and is well-positioned for growth in 2026 with multiple catalysts, including deeper penetration in primary care and population health through AI partnerships [3] - iRhythm's clinical evidence program, including AVALON and CAMELOT publications, supports the clinical superiority of its Zio LTCM product, which is expected to expand into additional populations and care settings [3] Financial Outlook - For full year 2025, revenue is anticipated to exceed the high end of the previously stated guidance range of $740 million, driven by record revenue unit volume in Q4 2025 [7] - The company expects revenue for 2026 to be approximately $870 million to $880 million, representing a year-over-year growth of about 17% to 18%, with an adjusted EBITDA margin of approximately 11.5% to 12.5% [7] Clinical Evidence - Recent real-world evidence from over 1.4 million patients reinforces the clinical superiority of Zio LTCM, with data demonstrating consistent performance in Asian populations and validating successful at-home self-application for earlier detection in at-risk populations [7]